Benjamin F Cravatt

La Jolla, CA, United States of America

Benjamin F Cravatt

This inventor holds 31 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Chemical Biology. Top assignees: Scripps Research Institute, Abide Therapeutics, Inc., Vividion Therapeutics, Inc.. Active years: 1995-2024.

USPTO Granted Patents = 31 

% Patents Active = 80.6

 

 

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 280(Granted Patents)


Location History:

  • San Diego, CA (US) (1995 - 2024)
  • La Jolla, CA (US) (2001 - 2024)

Company Filing History:


Years Active: 1995-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Carbamate Compounds
Serine Hydrolase
Cereblon Modulators
Lipid Probes
Cysteine-Reactive Ligands
Protein Degradation
Fatty-Acid Amide
Inhibitors
Photoreactive Ligands
Neurobehaviors
Enzyme Regulation
Proteomic Analysis
31 patents (USPTO):Explore Patents

Title: The Innovative Journey of Benjamin F. Cravatt

Introduction: Benjamin F. Cravatt is a renowned inventor based in La Jolla, California, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Benjamin F. Cravatt holds several patents in the areas of drug discovery, enzyme activity modulation, and proteomics, showcasing his continuous innovation in the industry.

Career Highlights: With a distinguished career spanning over two decades, Cravatt has held key research positions at leading institutions, driving forward cutting-edge research in biochemistry and chemical biology.

Collaborations: Throughout his career, Benjamin F. Cravatt has collaborated with top researchers, pharmaceutical companies, and academic institutions globally, fostering a culture of innovation and knowledge exchange.

Conclusion: Benjamin F. Cravatt's relentless pursuit of innovation and his commitment to advancing the field of biotechnology make him a true pioneer in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…